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Objective: This study was conducted to determine whether plasma total homocysteine (tHcy) and the methylenete-
trahydrofolate reductase (MTHFR) C677T polymorphism are associated with abdominal aortic aneurysm (AAA) and
aortic diameter.
Methods: This was a cross-sectional study set in Western Australia of 4248 community-dwelling men aged 70 to 88 years.
Infrarenal aortic diameter was measured using ultrasound scan, tHcy was measured by immunoassay, and MTHFR 677T
polymorphism was detected by polymerase chain reaction.
Results: Adjusted multinomial logistic regression analysis showed the odds of having an AAA (aortic diameter $30 mm)
for men with high tHcy ($15 mmol/L) compared with those with normal tHcy (<15 mmol/L) was 1.45 (95% conﬁdence
interval [CI], 1.10-1.91). Every 5-mmol/L increment in tHcy was associated with 0.15-mm (95% CI, 0.01-0.28 mm)
increase in mean aortic diameter. The tHcy concentration was higher in MTHFR TT homozygote individuals than in
wild-type CC individuals. There was, however, no apparent association between MTHFR C677T polymorphism with
AAA (TT vs CC genotype: odds ratio, 0.97; 95% CI, 0.72-1.31) or aortic diameter (TT vs CC genotype: mean increment
of 0.01 mm; 95% CI, L0.63 to 0.65 mm).
Conclusions: Elevated tHcy is associated with the presence of AAA in older men. There is also a positive dose-response
relationship between tHcy and abdominal aortic diameter. Longitudinal studies and clinical trials of lowering tHcy are
required to assess whether these relationships are causal. (J Vasc Surg 2013;58:364-70.)Abdominal aortic aneurysm (AAA) affects w5% of
men aged $65 years.1 Many of the risk factors for AAA
are similar to those for atherosclerosis, including age,
family history, smoking, dyslipidemia, hypertension, and
obesity.2,3 AAA has traditionally been regarded as a conse-
quence of atherosclerosis.4 However, epidemiologic differ-
ences, such as the inverse association of diabetes with
AAA, suggest disparate pathogenesis.5,6 Interest in the
cause of AAA has been stimulated by the current absence
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://dx.doi.org/10.1016/j.jvs.2013.01.046Homocysteine (Hcy) is a nonprotein amino acid
derived from the hepatic metabolism (demethylation) of
the essential sulfur-containing amino acid, methionine.
It is a substrate for three competing metabolic path-
ways. Hcy can be remethylated to methionine through
(1) a “salvage pathway” (the folate cycle), a process that
requires folate and B vitamins as cofactors, and (2) the
hepatic betaine-Hcy-methyltransferase reaction. It can
also be irreversibly converted via the trans-sulfuration
pathway in the liver and kidney to cystathionine and
cysteine. Elevated plasma total Hcy (tHcy) has been exten-
sively correlated with vascular events, including myocardial
infarction and stroke.8,9 Its association with AAA is
controversial, however, because previous studies have
provided discordant ﬁndings.10-16 The possibility of
reverse causality bias and residual confounding in these
studies precluded the establishment of a causal link
between tHcy and AAA.
Clinical studies have used the principle of Mendelian
randomization to explore the nature of the association
between tHcy and AAA, and their results have been equiv-
ocal.10,11,17-19 This is based on the concept that the
random assortment of alleles at the time of gamete forma-
tion creates a randomized trial of genetic polymorphisms
with a greater or lower expression of the relevant protein
from birth onward, and hence, the relationship between
the genetic variant, the risk factor of interest, and the
outcome is not susceptible to the common biases or
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It has been well documented that a commonly occurring
methylenetetrahydrofolate reductase (MTHFR) gene variant,
677T, encodes a defective enzyme with reduced catalytic
activity in the formation of 5-methyltetrahydrofolate.
The latter is the methyl donor needed for the conversion
of Hcy to methionine, thereby increasing basal plasma tHcy
byw20%.21On the basis of the theory ofMendelian random-
ization, the MTHFR C677T genotypes should have no
direct effect on AAA other than that mediated by tHcy
concentration.22
In this study, we sought to determine whether any rela-
tionship exists between tHcy and the presence of AAA and
aortic diameter in a large cohort of community-dwelling
men aged 70 to 88 years, while accounting for the tradi-
tional risk factors for AAA and other comorbidities. In an
attempt to further explore the potential causal role of
tHcy on AAA, we also investigated the association between
the MTHFR C667T polymorphism with AAA and aortic
diameter in this cohort of older men.
METHODS
The Human Research Ethics Committee of the
University of Western Australia approved the protocol for
the Health in Men Study (HIMS), which was conducted
in accordance with the Helsinki Declaration for Human
Rights.
Study design and participants. We conducted a
cross-sectional study of participants from the HIMS,
which has been described in detail elsewhere.23 In brief,
12,203 community-dwelling men aged 65 to 83 years
participated in a trial of screening for AAA. Each man
completed a health assessment between 1996 and 1999
(HIMS Wave 1). In 2001 to 2004, 5154 men responded
to the second phase of this study (HIMS Wave 2), and
blood samples were collected from 4249 of these
individuals.
Outcome of interest. The abdominal aortic diameter
was measured during HIMS Wave 1. The greatest trans-
verse and anteroposterior diameter of the infrarenal aorta
was measured using a Toshiba Capasee ultrasound
machine with a 3.75-MHz probe (Toshiba Australia,
North Ryde, NSW, Australia). The reproducibility of these
ultrasound measurements has been previously reported.24
An AAA was considered present if the abdominal aortic
diameter was $30 mm.
Biochemical analyses. Blood samples were collected
during HIMS Wave 2 between 0800 and 1030. Plasma
was separated from the blood samples #1 hour of collec-
tion and stored at 80C until assayed. Presence of tHcy
was measured by ﬂuorescence polarization immunoassay
on an IMx analyzer (Abbott Laboratories, Abbott Park,
Ill).25 The interassay coefﬁcient of variation was 4%.
Genomic DNA was isolated from nucleated blood cells by
using the Triton X-100 method, and the nt677C/T
mutation was determined using polymerase chain reaction.
HinfI restriction enzyme digestion was performed directly
in the polymerase chain reaction tube at 37C for 4 hoursbefore analysis of restriction fragments by polyacrylamide
gel electrophoresis, as previously described.26 Allele
frequencies were estimated by gene counting, and the
genotype distribution was compared with those expected
under Hardy-Weinberg equilibrium.
Serum high-sensitivity C-reactive protein was measured
with assay on a BNII analyzer (Dade Behring, Birming-
ham, UK). Serum creatinine, glucose, cholesterol, low-
density lipoprotein, and triglycerides were measured
with a Roche Hitachi 917 analyzer (Roche Diagnostics,
Indianapolis, Ind).
Other explanatory variables. Variables available from
the Wave 2 assessment were age, smoking status (current,
former, or never smoker), and taking B-vitamin supple-
ments or not. Data fromWaves 1 and 2 were used to deter-
mine the prevalence of cardiovascular disease (CVD; self-
reported history of angina, myocardial infarction, heart
failure, coronary artery bypass grafting, coronary angio-
plasty, carotid endarterectomy, aortic bypass surgery,
peripheral arterial surgery or stroke, or use of antiplatelet
medications for these conditions), hypertension (self-re-
ported diagnosis, use of antihypertensive medications, or
measured blood pressure$140/90mmHg), diabetes (self-
reported diagnosis or use of glucose-lowering medication,
or fasting glucose of $7 mmol/L or nonfasting glucose of
$11 mmol/L) and dyslipidemia (self-reported diagnosis,
use of lipid-lowering medication, or fasting low-density
lipoprotein $3.4 mmol/L, high-density lipoprotein
<0.9 mmol/L, triglycerides $1.8 mmol/L, or total
cholesterol $5.5 mmol/L).
To calculate the weighted Charlson Comorbidity
Index (CCI),27 we obtained the health records and death
certiﬁcates (until the end of Wave 2) from the Western
Australian Data Linkage System. This database provides
electronic linkage to the state’s use of health services and
medical morbidities.28 Seventeen common medical condi-
tions that predict 1-year mortality were accounted for:
myocardial infarction, congestive heart failure, peripheral
arterial disease, cerebrovascular disease, dementia, chronic
pulmonary disease, connective tissue disease, ulcers, liver
disease, diabetes (including diabetes with end-organ
damage), hemiplegia, renal disease, leukemia, lymphoma,
other tumors, metastatic tumors, and acquired immunode-
ﬁciency syndrome. The number and seriousness of these
comorbid diseases were evaluated by assigning integer
weights to these conditions using adjusted relative risks
and developing a composite index score that ranged from
0 to 37.27
Height, weight, and waist circumference were
measured during Wave 2 in accordance with guidelines of
the International Society for the Advancement of Kinan-
thropometry.29 Height and weight were used to calculate
body mass index (BMI, kg/m2).
Statistical analysis. Data were analyzed using Stata
11.1 software (StataCorp, College Station, Tex). Descrip-
tive statistics were calculated for the demographic, lifestyle,
and clinical variables according to the presence or absence of
AAA. Concentration of tHcy was dichotomized into high
Table I. Demographic, lifestyle, and clinical
characteristics of the study population according to the
presence or absence of abdominal aortic aneurysm (AAA)
Variablea
AAA
(n ¼ 318)
No AAA
(n ¼ 3930) P
Age, years 77.7 6 4.1 76.5 6 3.6 <.001
Smoking
Current smoker 37 (11.7) 179 (4.6) <.001
Former smoker 240 (75.7) 2371 (60.3)
Never smoked 41 (12.6) 1380 (35.1)
Taking B-vitamin
supplement
15 (4.7) 231 (5.9) .395
Cardiovascular disease 208 (65.4) 1625 (41.3) <.001
Diabetes 67 (21.1) 596 (15.2) .005
Hypertension 307 (96.5) 3452 (87.8) <.001
Dyslipidemia 262 (82.4) 2740 (69.7) <.001
CCI $5 29 (9.1) 146 (3.7) <.001
BMI, kg/m2 27.1 6 3.8 26.5 6 3.6 .006
Aortic diameter, mm 36.4 6 7.5 21.8 6 2.6 <.001
Plasma tHcy, mmol/L 15.1 6 6.1 13.2 6 5.1 <.001
hsCRP, mg/L 4.9 6 8.4 3.7 6 7.3 .008
Creatinine, mmol/L 104.8 6 40.9 92.8 6 30.6 <.001
BMI, Body mass index; CCI, Charlson Comorbidity Index; hsCRP, high-
sensitivity C-reactive protein; tHcy, total homocysteine.
aContinuous data are presented as mean 6 standard deviation and categoric
data as number (%).
JOURNAL OF VASCULAR SURGERY
366 Wong et al August 2013tHcy ($15 mmol/L) and normal tHcy (<15 mmol/L), as
determined by the laboratory’s reference range. Aortic
diameter was divided into intervals of <19, 19 to 22, 23
to 29, and $30 mm, based on standard deviations (SDs)
of logarithmic diameter.4 tHcy was modeled as categoric
and continuous variables according to whether tHcy was
$15 mmol/L, per 5-mmol/L increment in tHcy, and
doubling of tHcy concentration (by dividing the natural
logarithm of tHcy by the natural logarithm of 2).
Multinomial logistic regression analyses were per-
formed to assess for any dose-response relationship
between tHcy and aortic diameter intervals, using a refer-
ence interval of 19 to 22 mm. Linear regression analyses
were performed with aortic diameter modeled as a contin-
uous variable. Analyses were also repeated after logarithmic
transformations of the aortic diameter due to its positively
skewed distribution. Adjustments were made for age,
smoking, CVD, diabetes, hypertension, dyslipidemia,
CCI, BMI, and serum creatinine as potential confounders.
The results are reported as odds ratios (ORs) with 95%
conﬁdence intervals (95% CIs). P <.05 was considered
statistically signiﬁcant.
Descriptive statistics were used to calculate the distri-
bution of the MTHFR genotypes according to AAA. Anal-
ysis of variance and linear regression analysis were used to
explore the association of the MTHFR genotypes with
tHcy. Linear and multinomial logistic regression analyses
were performed to investigate the relationship between
the MTHFR polymorphism with aortic diameter and
AAA, using the CC genotype and aortic diameter interval
of 19 to 22 mm as references.RESULTS
Sociodemographic, clinical, and biochemical charac-
teristics of the study population, according to the presence
or absence of AAA, are reported in Table I. Complete
tHcy and aortic diameter measurements were available
for 4248 men, aged 70 to 88 years; of these, 1120
men (26.3%) had high tHcy ($15 mmol/L) and the
mean 6 SD tHcy concentration for the cohort was
13.4 6 5.6 mmol/L. None of the participants had homo-
cystinuria. AAA (aortic diameter $30 mm) was present in
318 men (7.5%), and the mean 6 SD aortic diameter for
the cohort was 22.8 6 4.9 mm (range, 15.9-79.2 mm).
Association of tHcy with AAA. An incremental asso-
ciation was found between tHcy and aortic diameter inter-
vals (P < .001; Table II). Adjustments were made for age,
smoking, CVD, diabetes, hypertension, dyslipidemia, CCI,
BMI, and serum creatinine. At a reference interval of 19
to 22 mm, the OR of having an AAA (aortic diameter
$30 mm) for men with high tHcy ($15 mmol/L)
compared with those with normal tHcy (< 15 mmol/L)
was 1.45 (95% CI, 1.10-1.91). The association persisted
when tHcy was modeled as continuous variables. The Fig
demonstrates the OR of having an AAA with changing
tHcy concentrations, with tHcy entered into the models as
restricted cubic splines.30Association of tHcy with aortic diameter. Multivar-
iate linear regression analyses showed men with high tHcy
had a 0.41-mm (95% CI, 0.06-0.77 mm) larger mean
aortic diameter than those with normal tHcy concentra-
tions. Every 5-mmol/L increment in tHcy was associated
with 0.15-mm (95% CI, 0.01-0.28 mm) larger mean aortic
diameter. Doubling of tHcy was associated with 0.39-mm
(95% CI, 0.05-0.73 mm) larger mean aortic diameter.
These associations persisted when aortic diameter was
log-transformed (data not shown).
Sensitivity analyses. We performed a sensitivity
analysis by excluding men who reported taking B vitamin
supplements. When this was done, the odds of having
an AAA for men with high tHcy and not taking B vitamin
supplements were not altered to a great extent compared
with those with normal tHcy (OR, 1.48; 95% CI,
1.11-1.96). When high-sensitivity C-reactive protein was
included in the model of tHcy and AAA, the effect
estimate remained similar (OR, 1.44; 95% CI, 1.09-1.90).
Association of MTHFR polymorphism with AAA
and aortic diameter. MTHFR polymorphism data were
available for 4130 men. The distribution of the MTHFR
genotypes was similar for participants with and without
AAA: CC, 281 (45.5%); CT, 267 (43.3%); and TT, 69
(11.2%) for men with AAA, and CC, 1549 (44.1%); CT,
1566 (44.6%); and TT, 398 (11.3%) for the remaining
men (P ¼ .795). The genotype distribution was in
Hardy-Weinberg equilibrium (exact test, P ¼ .773).
Mean 6 SD aortic diameters were 24.1 6 6.5, 23.8 6 6.1,
and 24.1 6 6.2 mm for men with the CC, CT, and TT
genotypes, respectively (F ¼ 1.08, P ¼ .341). As reported
previously.31 The mean (6 SD) tHcy concentration
Table II. Multinomial logistic regression modelsa evaluating the association of plasma total homocysteine (tHcy) with
aortic diameter intervals in community-dwelling older men
Variables
Aortic diameter intervals
<19 mm (n ¼ 440) 19-22 mm (n ¼ 2427) 23-29 mm (n ¼ 1063) $30 mm (n ¼ 318)
tHcy, mmol/Lb 12.8 6 5.0 13.1 6 5.1 13.8 6 5.1 15.1 6 6.1
tHcy $15 mmol/Lc 0.76 (0.58-1.00) Reference 1.20 (1.00-1.43) 1.45 (1.10-1.91)
Per 5-mmol/L increment in tHcyc 0.90 (0.79-1.02) Reference 1.06 (0.99-1.14) 1.12 (1.02-1.23)
Doubling of tHcyc 0.76 (0.58-0.97) Reference 1.14 (0.96-1.36) 1.50 (1.14-1.99)
BMI, Body mass index; CCI, Charlson Comorbidity Index; CI, conﬁdence interval; OR, odds ratio.
aAdjusted for age, smoking status, cardiovascular disease, hypertension, dyslipidemia, diabetes, CCI score, BMI, and serum creatinine.
bData shown as mean 6 standard deviation or the OR (95% CI).
cOR (95% CI) presented for high tHcy ($15 mmol/L) relative to normal tHcy (<15 mmol/L), and per 5-mmol/L increment in tHcy and doubling of tHcy.
0
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O
R
Fig. Odds ratio (OR; solid line) of an abdominal aortic aneurysm
(AAA) (aortic diameter $30 mm) with changing plasma total
homocysteine (tHcy) levels is shown. Levels of tHcy are entered
into the models as restricted cubic splines (3 knots) with a refer-
ence value of 9 mmol/L (median of the lowest quartile of tHcy
concentrations). The tHcy scale of 8 to 22 mmol/L relates to the
range between the 5th and 95th percentiles of values (n ¼ 3823).
The dashed lines denote 95% conﬁdence interval (CI).
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men with the CC, CT and TT genotypes, respectively
(F ¼ 10.16, P < .001).
Linear and multinomial logistic regression analyses
showed no apparent association between MTHFR poly-
morphism with aortic diameter and AAA (Table III).
The OR of having an AAA was 0.95 (95% CI,
0.79-1.15) for men with the CT genotype and 0.97
(95% CI, 0.72-1.31) for men with the TT genotype
compared with those with the CC genotype. Men with
the CT genotype had a reduction of 0.29 mm (95%
CI, 0.69 to 0.12 mm) in mean aortic diameter; however,
men with the TT genotype had an increment of 0.01 mm
(95% CI, 0.63 to 0.65 mm) in diameter.
DISCUSSION
Our results provide further evidence for an association
between elevated tHcy and the presence of AAA,independent of the traditional CVD risk burden and other
comorbidities. The risk of having an AAA for men with
high tHcy is 45% higher compared with those with normal
tHcy concentrations. tHcy is also correlated with abdom-
inal aortic diameter in a positive dose-response relationship,
with every 5-mmol/L increment in tHcy being associated
with 0.15-mm larger mean aortic diameter. These ﬁndings
suggest that elevated tHcy could be an epiphenomenon or
have a role in the development of an AAA in aging men.
The strengths of this study include the large sample
size of robustly characterized, population-based, commu-
nity-dwelling older men. We were able to comprehensively
adjust for potential confounders in our multivariate anal-
yses, including age, smoking, CVD, and risk factors that
have established associations with tHcy and AAA. The
addition of other variables that might modify the relation-
ship, including statin and antiplatelet therapies, did not
signiﬁcantly alter the effect estimates. Measurement of
the aortic diameter was performed in a standardized proce-
dure using ultrasound imaging.
A major limitation would be that blood samples were
obtained from the participants several years (5.7 6 0.9
years) after the baseline aortic diameter measurements. It
is possible that the aortic diameters in our cohort could
have increased by a small margin in the time interval.32
However, it is unlikely that the small number of interval
cases of AAA would have substantially altered the results.
The cross-sectional design of our study and the lack of
serial assessments of tHcy concentration or aortic diameter
also preclude determination of causality. Our ﬁndings
could reﬂect reverse causality, with higher comorbidities
in men with an AAA at baseline leading to less physical
activity and poorer diet, and consequently, higher tHcy
concentrations.
Our ﬁndings are conservative due to a possible
“healthy survivor” effect. Participants who had responded
for the Wave 2 assessment were younger (P < .001), more
physically active (P < .001), and had fewer self-reported
comorbidities (P < .001) during Wave 1 compared with
the nonrespondents of the follow-up study. This self-
selection of participants might have biased our ﬁndings
toward lower tHcy concentrations in our cohort compared
Table III. Multinomial logistic regression models evaluating the association of the methylenetetrahydrofolate reductase
(MTHFR) C677T polymorphism with aortic diameter intervals in community-dwelling older men
MTHFR C677T
polymorphismsa
Aortic diameter intervals
<19 mm 19-22 mm 23-29 mm $30 mm
CT genotype 1.18 (0.94-1.48) Reference 0.99 (0.84-1.16) 0.95 (0.79-1.15)
TT genotype 0.91 (0.62-1.33) Reference 1.10 (0.86-1.41) 0.97 (0.72-1.31)
CI, Conﬁdence interval; OR, odds ratio.
aOR (95% CI) presented for CT and TT genotypes relative to CC genotype.
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toward the null hypothesis, leading to an underestimation
of the magnitude of the association between tHcy with
AAA.
Finally, our data for B vitamin supplementation was
based on self-reported history. By not having access to B
vitamin concentrations, we were therefore unable to deﬁn-
itively account for possible effects due to the prevailing
folate concentration.
Hcy inﬂuences a range of molecular pathways of poten-
tial relevance to the pathogenesis of AAA, some of which
may be different from those implicated in atherosclerosis.
Experimentally, Hcy induces endothelial dysfunction and
matrix remodeling in part by stimulating the secretion of
matrix metalloproteases and release of reactive oxygen
species, which are implicated in AAA pathogenesis.33-35
Immune mechanisms may also be important in AAA
formation.36,37 Hcy stimulates chemokine and cytokine
secretion from cultured human monocytes and has been
implicated in suppressing regulatory T-cell function.38,39
Homocysteinylation, which is a manifestation of Hcy
toxicity, is characterized by a nonenzymatic chemical reac-
tion that can cause structural protein inactivation, with
consequent destruction of the aortic wall.40 A recent
animal study demonstrated that hyperhomocysteinemia
contributes to the development of AAA through aortic
adventitial inﬂammation, a process that is reversible with
folic acid supplementation.41
Although we have demonstrated a statistically signiﬁ-
cant quantitative association between elevated tHcy with
the enlargement of the abdominal aortic diameter by
mere fractions of a millimeter, these small differences are
of limited clinical signiﬁcance for an individual person.
Despite this, ﬁndings from previous experimental studies
have indicated that this association is biologically plausible,
suggesting the possibility that Hcy-lowering strategies
could limit AAA formation in humans.
To our knowledge, this is the largest epidemiologic
study to demonstrate an independent association between
elevated tHcy with the presence of AAA and aortic diam-
eter. Brunelli et al11 were the ﬁrst to conduct a case-
control study of 58 men and reported a sixfold increase
in the likelihood of having AAA with hyperhomocysteine-
mia (OR, 6.0; 95% CI, 1.2-29.6). Subsequent studies
further implicated tHcy in the pathophysiology of
AAA.10,14,42-44 Researchers also found that patients withAAA had lower levels of vitamin B12, which is important
in the regulation of tHcy concentrations.13 However,
discrepant results have emerged from other studies that
may be limited by patient selection and residual confound-
ing.12,15,16 Further exploration of this relationship with
adequately powered longitudinal studies and clinical trials
would be required to have an improved understanding
of any role homocysteine metabolism plays in AAA
pathogenesis.
In our study, tHcy concentrations were elevated with
the MTHFR 677T variant compared with the 677C or
“wild” allele. However, no obvious association was found
between the T allele and the presence of AAA and aortic
diameter. We performed a retrospective power calculation
(80% power with an a ¼ .05) and deduced that the study
would require >1 million participants (w300,000 men
with the TT genotype) to detect an effect size of 0.03-mm
increase in mean aortic diameter associated with
a 1-mmol/L increment in tHcy (effect size derived from
our multivariate linear regression analysis). Similarly, other
studies would have been clearly underpowered to establish
an association.10,11,17-19 When a meta-analysis of these
studies was conducted (w2300 individuals), an increased
risk of AAA associated with the T allele variant (risk ratio,
1.14, 95% CI, 1.08-1.21) was obtained.45 This is supportive
of a causal link between hyperhomocysteinanemia and AAA.
CONCLUSIONS
Elevated tHcy is associated with the presence of AAA
in older men, independent of the traditional CVD risk
burden and other comorbidities. There is also a positive
dose-response relationship between tHcy and abdominal
aortic diameter, suggesting a role of tHcy in AAA develop-
ment in aging men. However, Mendelian randomization to
the MTHFR TT genotype is not associated with AAA or
aortic diameter, despite higher tHcy. The discordance in
these ﬁndings may reﬂect confounding or random error.
Longitudinal studies and clinical trials of lowering tHcy
are required to assess whether these relationships are causal.
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